Eisai
Leqembi Makes History as First EU-Approved Drug to Target Root Cause of Alzheimer’s Disease
2025-04-15
FDA Granted Eisai and Biogen’s New Alzheimer’s Drug a Traditional Approval, Making Medicare Coverage Possible
2023-07-11
Biogen Concludes $900 Million Settlement Before Posting Positive Data From Alzheimer’s Trial
2022-09-28
LATEST
Boehringer Ingelheim and Tempus AI Partner in Multi-Year Collaboration to Enhance Oncology Drug Development
2025-05-15
Study: Aligning U.S. Drug Prices with Europe Could Reduce American Life Expectancy by Six Months
2025-05-15
Tribal Leaders Warn Senators: Federal Health Funding Cuts Threaten Native American Health.
2025-05-14